论文部分内容阅读
目的观察紫彬醇与顺铂联合化疗治疗晚期食道癌(AEC)的临床疗效以及安全性。方法 64例AEC患者,随机分为观察组与对照组,各32例,观察组行紫彬醇联合顺铂化疗,对照组行顺铂联合5-氟尿嘧啶化疗,比较两组的疗效。结果观察组的总有效率以及稳定率分别为40.6%、81.2%,均显著高于对照组的28.1%、62.5%(P<0.05);观察组的生存期为(10.4±4.1)个月,较对照组的(7.2±3.3)个月显著延长,1、2年生存率显著高于对照组(P<0.05);观察组的化疗不良反应发生率显著低于对照组(P<0.05)。结论紫彬醇与顺铂联合化疗治疗AEC疗效明显优于顺铂联合5-氟尿嘧啶,且药物不良反应更少,值得推广应用。
Objective To observe the clinical efficacy and safety of combination of Zibenol and cisplatin in the treatment of advanced esophageal cancer (AEC). Methods Sixty-four patients with AEC were randomly divided into observation group and control group, with 32 cases in each group. The observation group was treated with combination of carboplatin and cisplatin and the control group with cisplatin combined with 5-fluorouracil. The curative effect was compared between the two groups. Results The total effective rate and the stability rate of the observation group were 40.6% and 81.2%, respectively, which were significantly higher than those of the control group (28.1% and 62.5%, P <0.05). The survival rate of the observation group was 10.4 ± 4.1 months, Compared with the control group, the survival rate was significantly longer than that of the control group (7.2 ± 3.3) months, and the 1-year and 2-year survival rates were significantly higher than those of the control group (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that of the control group (P <0.05). Conclusions The combination of Zibinol and cisplatin in the treatment of AEC is superior to cisplatin and 5-fluorouracil in treating AEC with less side effects. It is worth popularizing and applying.